Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$78.70M+1993.16%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Raul R. Rodriguez
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 173
- Beta
- 1.20
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 4.12
Financials
Revenue
$78.70M+1993.2%Net Income
$17.29MEBITDA
$25.21MFree Cash Flow
$30.65MEPS (diluted)
$0.88Shares Outstanding (diluted)
19.57M+105.0%Operating Expenses
$46.60MCash & Debt
$95.33MReturn of Capital
$3.74MRevenue by Segment (annual)
$216.30MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $294.28M | $367.02M | $20.40 |
| 2024 | $179.28M | $17.48M | $0.99 |
| 2023 | $116.88M | $-25.09M | $-1.44 |
| 2022 | $120.24M | $-58.57M | $-3.40 |
| 2021 | $149.24M | $-17.91M | $-1.10 |
| 2020 | $108.62M | $-29.74M | $-1.80 |
| 2019 | $59.29M | $-66.55M | $-4.00 |
| 2018 | $44.51M | $-70.48M | $-4.40 |
| 2017 | $4.48M | $-77.99M | $-6.17 |
| 2016 | $20.38M | $-69.22M | $-7.33 |
| 2015 | $28.89M | $-51.46M | $-5.82 |
| 2014 | $8.25M | $-90.91M | $-10.37 |
| 2013 | $7.15M | $-89.03M | $-10.20 |
| 2012 | $2.25M | $-98.84M | $-6.14 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $29.98
- Implied price
- $539.67
- Return from $47.79
- 62.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $268.31 — today's price is already 82.2% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 35.9% | 42.1% | 47.4% | 52.0% | 56.1% |
| 3.0% | 42.8% | 49.3% | 54.9% | 59.7% | 64.0% |
| 8.0% | 49.7% | 56.6% | 62.4% | 67.5% | 72.0% |
| 13.0% | 56.7% | 63.8% | 69.9% | 75.2% | 80.0% |
| 18.0% | 63.6% | 71.1% | 77.4% | 83.0% | 87.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+11.11%Social Signal Score
Mentions (3)
- Newsprnewswire.com·4d ago·Neutral
…unces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).
View source ↗ - Newsprnewswire.com·34d ago·Neutral
Rigel to Participate in Upcoming September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September: Citi's 2026 Biopharma Back to School Conference in New York, NY Rigel will participate in one-on-one mee…
View source ↗ - Newsprnewswire.com·54d ago·Negative
…atment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANUTM (vepdegestrant) is now available by prescription in the United States for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 …
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $0.92 per share
Typical surprise +66.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.88 vs $0.09beat
- Tue, May 5$0.44 vs $0.74miss
- Tue, Mar 3$1.14 vs $1.33miss
- Tue, Nov 4$1.46 vs $0.93beat
- Tue, Aug 5$3.28 vs $1.97beat
- Tue, May 6$0.63 vs $0.14beat
Estimates and results for RIGL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RIGL officers and directors.
- Bought
- —
- Sold
- $470k
0 trades
7 trades
- Ali-jackson Kamilsold
- Ali-jackson Kamilsold
- Moos Walter Hsold
- Schorno Dean Lsold
- Santos David Asold
- Schorno Dean Lsold
- Santos David Asold
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RIGL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.